154 related articles for article (PubMed ID: 36263608)
1. The effect of burosumab on intact and C-terminal FGF23 measurements.
Ashrafzadeh-Kian SL; Ito N; Srivastava T; Garg U; Kato H; Algeciras-Schimnich A; Bornhorst JA
Clin Endocrinol (Oxf); 2023 Aug; 99(2):152-157. PubMed ID: 36263608
[TBL] [Abstract][Full Text] [Related]
2. FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference.
Piketty ML; Brabant S; Souberbielle JC; Maruani G; Audrain C; Rothenbuhler A; Prié D; Linglart A
Clin Chem Lab Med; 2020 Oct; 58(11):e267-e269. PubMed ID: 32653872
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
[TBL] [Abstract][Full Text] [Related]
4. Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).
Bai X; Levental M; Karaplis AC
J Clin Endocrinol Metab; 2022 Sep; 107(10):2777-2783. PubMed ID: 35896139
[TBL] [Abstract][Full Text] [Related]
5. Burosumab: First Global Approval.
Lamb YN
Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
[TBL] [Abstract][Full Text] [Related]
6. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S
J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
Takashi Y; Kawanami D; Fukumoto S
Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):170-175. PubMed ID: 38687287
[TBL] [Abstract][Full Text] [Related]
8. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
Takashi Y; Kawanami D; Fukumoto S
Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
[TBL] [Abstract][Full Text] [Related]
9. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA; Glorieux FH; Whyte MP; Munns CF; Ward LM; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Mao M; Chen CY; Skrinar A; San Martin J; Portale AA
Lancet; 2019 Jun; 393(10189):2416-2427. PubMed ID: 31104833
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
11. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
13. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
[TBL] [Abstract][Full Text] [Related]
14. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
Balani S; Perwad F
Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
[TBL] [Abstract][Full Text] [Related]
15. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
[TBL] [Abstract][Full Text] [Related]
16. Burosumab: Current status and future prospects.
Goyal A; Tandon N
Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
[TBL] [Abstract][Full Text] [Related]
17. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
18. Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
Kubota T; Namba N; Tanaka H; Muroya K; Imanishi Y; Takeuchi Y; Kanematsu M; Sun W; Seino Y; Ozono K
Adv Ther; 2023 Apr; 40(4):1530-1545. PubMed ID: 36719566
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking.
Kanhasut K; Tharakaraman K; Ruchirawat M; Satayavivad J; Fuangthong M; Sasisekharan R
Sci Rep; 2022 Aug; 12(1):14754. PubMed ID: 36042241
[TBL] [Abstract][Full Text] [Related]
20. Intact fibroblast growth factor 23 and fragments in plasma from Gambian children.
Braithwaite V; Bruggraber SF; Prentice A
Osteoporos Int; 2013 Mar; 24(3):1121-4. PubMed ID: 22648001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
